KMID : 1040620230290000103
|
|
Clinical and Molecular Hepatology 2023 Volume.29 No. 0 p.103 ~ p.122
|
|
Screening strategy for non-alcoholic fatty liver disease
|
|
Saisai Zhang
Lung-Yi Mak Man-Fung Yuen Wai-Kay Seto
|
|
Abstract
|
|
|
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liverrelated complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening.
|
|
KEYWORD
|
|
NAFLD, Metabolic diseases, Diabetes mellitus, Fatty liver, Fibrosis
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|